Biohit Oyj - Total number of voting rights and capital

Biohit Oyj B-shares Subscribed with Stock Options II 2013

Biohit Oyj Stock Exchange Release December 12, 2014 at 9:30 a.m. local time
(EET) 

A total number of 55,000 new Biohit Oyj B-shares have been subscribed for with
stock options II 2013 during November 5th, 2014 and November 13th, 2014. These
shares have been entered into the trade register on December 12, 2014, as of
which date the new shares will establish equal shareholder rights with the
company's existing B-shares. Public trading is expected to begin on NASDAQ OMX
Helsinki as of December 15, 2014 together with the existing B-shares. 

The share subscription price was EUR 2.2766 per share (40,000 shares Nov 5th)
and EUR 3,00 (15,000 shares Nov 13th) respectively. The entire subscription
price of EUR 136,064 will be credited to the reserve for invested
non-restricted equity, and the company share capital remains unchanged. The
shares have no nominal value. 

After the subscription the number of all Biohit Oyj's shares will rise into
14,135,593 shares (14,080,593) and B-shares will rise into 11,160,093 shares
(11,105,093). The new shares will correspond to a percentage of 0.4% of Biohit
Oyj's total number of shares and 0.08% of the voting rights after registration. 

The share subscription period with stock options II 2013 began on July 1, 2013
and will end June 30, 2015. The option schemes are based on the Biohit Oyj
board resolution of June 19, 2013 and the Annual General Meeting authorization
of April 13, 2011. The terms and conditions of the option schemes with
additional information are available on Biohit Oyj website at
www.biohithealthcare.com. 


Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com